



HAL
open science

Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems

Yupeng Fu, Ying Ding, Litao Zhang, Yongmin Zhang, Jiang Liu, Peng Yu

► **To cite this version:**

Yupeng Fu, Ying Ding, Litao Zhang, Yongmin Zhang, Jiang Liu, et al.. Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems. *European Journal of Medicinal Chemistry*, 2021, 217, pp.113372. 10.1016/j.ejmech.2021.113372 . hal-03369183

HAL Id: hal-03369183

<https://hal.sorbonne-universite.fr/hal-03369183>

Submitted on 7 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Poly Ethylene Glycol (PEG)-Related Controllable and Sustainable Antidiabetic Drug Delivery Systems

Yupeng Fu^a, Ying Ding^a, Litao Zhang^a, Yongmin Zhang^{a,b}, Jiang Liu^{a*}, Peng Yu^{a*}

^a China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin Key Laboratory of Industry Microbiology, College of Biotechnology, Tianjin University of Science & Technology, 300457 Tianjin, China

^b Sorbonne Université, CNRS, IPCM, UMR 8232, 4 Place Jussieu, 75005 Paris, France

* Corresponding authors e-mail address: liu.jiang@tust.edu.cn (Jiang Liu), yupeng@tust.edu.cn (Peng Yu)

ABSTRACT

Diabetes mellitus is one of the most challenging threats to global public health. To improve the therapy efficacy of antidiabetic drugs, numerous drug delivery systems have been developed. Polyethylene glycol (PEG) is a polymeric family sharing the same skeleton but with different molecular weights which is considered as a promising material for drug delivery. In the delivery of antidiabetic drugs, PEG captures much attention in the designing and preparation of sustainable and controllable release systems due to its unique features including hydrophilicity, biocompatibility and biodegradability. Due to the unique architecture, PEG molecules are also able to shelter delivery systems to decrease their immunogenicity and avoid undesirable enzymolysis. PEG has been applied in plenty of delivery systems such as micelles, vesicles, nanoparticles and hydrogels. In this review, we summarized several commonly used PEG-contained antidiabetic drug delivery systems and emphasized the advantages of stimuli-responsive function in these sustainable and controllable formations.

Keywords: PEG, drug delivery system, antidiabetic, stimulating responsive release, sustainable release


Content

1	Introduction	3
2	PEGylated micelles in antidiabetic treatments	9
3	PEGylated vesicles in antidiabetic treatments	15
4	PEGylated nanoparticles (NPs) in antidiabetic treatments	22
5	PEGylated hydrogels in antidiabetic treatments	27
6	Conclusion	33
	Reference	36

1 Introduction

Diabetes mellitus is a severe chronic metabolic disease which imposes enormous burdens both personally and socially¹. It is estimated that 4 million people died of diabetes and its complications in 2017, which has caused vast economic losses². Generally, diabetes is classified into three subtypes: type 1 diabetes mellitus (T1DM) is an autoimmune disease, induced by the destruction of pancreatic β -cells which produce insulin³, type 2 diabetes mellitus (T2DM) is generated by the insufficient insulin supply or the insulin resistance⁴, gestational diabetes mellitus (GDM) is a glucose intolerance which first diagnosed during pregnancy⁵. Among all these subtypes, T2DM is the biggest threat to public health, the figure for T2DM patients almost accounting for 90% of the total⁶. A wide range of diabetes therapies including behavioral⁷, nutritional⁸, physical⁹ and the most important, medicamentous therapies, have been adopted to alleviate diabetes and its complications.

Drug delivery systems (DDSs) plays a vital role in the clinical application of antidiabetic treatments since many antidiabetic drugs cannot achieve the ideal therapeutic effect without any assistance from a delivery system. Thus, appropriate DDSs are crucial in the designing of formulations. PEG-contained delivery systems are regarded as ideal options for the optimization of antidiabetic drug deliveries. PEG is a family of amphiphilic polymers¹⁰ that sharing the same skeleton of repeating ethylene glycol units $[(\text{CH}_2\text{CH}_2\text{O})_n]$ but with different molecular weights¹¹. The most commonly used PEGylated reagents are the linear types of PEG chains. Except for the linear type, various shapes of PEG derivatives had been developed to meet different functions of specific attempts (**figure 1**). The derivation of PEG allowed more functionalization sites to be accessed, that broken through the limitations of the linear type PEG¹², however, the derivation of PEG brought chemistry challenges in synthesis compared to the linear type PEG. Generally, PEGs have been extensively used in DDSs to ameliorate the physiochemical properties and bioactivity of various substrates¹³.



60
61 **Figure 1.** PEG and multiple derivatives obtained via different linking methods such as linear (A), 3-arm (B), 4-arm (C),
62 Y-shaped (D) and comb-like polymers (E)¹⁴.
63

64 PEG molecules consisting of the DDSs are able to shield DDSs and drugs by their long hydrophilic
65 chains. This distinctive architecture generally renders the delivery particles four characters: 1) enhanced
66 enzymatic stability; 2) expanded hydrodynamic volume; 3) reduced immunogenicity of the large
67 biomolecules and 4) decreased possibility of the macromolecules aggregation. These properties can
68 decrease the kidney clearance, prolong the internal lifespan and promote the stability of particles, which
69 lead to improved therapeutic effects¹⁵. Owing to its unique structure, PEG endows natural or artificial
70 materials with improved physiochemical properties and biodegradability¹⁶.

71 Besides, due to the absence of inherent bioactivity, antidiabetic PEGylated polymeric systems can
72 provide optimization of delivery and release process *in vivo* such as the prolonged half-life time¹⁷. Diverse
73 types of PEGylated antidiabetic DDSs including nanoparticles, microspheres, nanovesicles, micelles and
74 hydrogels are able to fit novel administration of drugs like transdermal¹⁸ and oral administration¹⁹ of
75 insulin and intelligent insulin injections²⁰ which are able to overcome the disadvantages of traditional
76 open-loop insulin delivery systems²¹. A number of studies have verified the advantages of PEGylated DDSs
77 in diabetes treatments (**table 1**).
78

Table 1. Part of the PEGylated DDSs applied in antidiabetic treatment

Loaded drug	DDS	Antidiabetic activity investigation model	Route of administration	Features
Insulin ²²	mPEG- <i>b</i> -P(GA- <i>co</i> -GPBA) micelles	Not applicable (N/A)	N/A	Glucose-responsive insulin release <i>in vitro</i>

Insulin ²³	PEG-PE micelles	BALB/c male mice	Intraperitoneal (i.p.) injection	Promote the renaturation of DTT-induced aggregated insulin
Insulin ²⁴	PEG/PNIPAM-P (Asp- <i>co</i> -AspPBA)/P (Asp- <i>co</i> -AspGA- <i>co</i> -AspNTA) complex micelles	STZ-induced mice	Subcutaneous (s.c.) injection	Protease resistance, improved blood glucose regulation capacity
Insulin ²⁵	PEG- <i>b</i> -P(AA- <i>co</i> -APBA)/P(AA- <i>co</i> -AGA) micelles	N/A	N/A	Enhanced glucose-responsive capacity
Insulin ²⁶	Microsphere loaded with CA-PLGA- <i>b</i> -(PEI-PEG) micelles-insulin conjugates	STZ-induced rats	S.c. injection	Reduced cytotoxicity, extended efficacy time
Insulin ²⁷	Insulin-deoxycholate composite micelles encapsulated by PCL-PEG-PCL vesicles	STZ-induced rats	S.c. injection	Improved encapsulation efficiency
Insulin ²⁸	PEG-P (Ser-ketal) nanovesicles	STZ-induced mice	S.c. injection	Acid-responsive insulin release <i>in vivo</i> with extended blood glucose regulation time
Insulin ¹⁸	Microneedle array loaded with mPEG- <i>b</i> -P(SerPBE) vesicles	STZ-induced mice	Transdermal administration	Painless administration with glucose-responsive insulin release
Insulin ²⁹	Microneedle array loaded with PEG-poly (Ser-S-NI) vesicles	STZ-induced mice	Transdermal administration	Enhanced and stable blood glucose regulation ability with low hypoglycemia risk
Insulin ³⁰	DSPE-PEG-coated DPPC liposomes	STZ-induced rats	Femoral venous cannula	Improved incorporation efficiency and stability, more uniform particle size
Insulin ³¹	PEG-PLGA nanoparticles	STZ-induced mice	S.c. injection	Sustain therapeutic effect with same minimum blood glucose level compared with free insulin
Insulin ³²	TPGS-emulsified PEG-capped-PLGA nanoparticles	STZ-induced rats	Oral administration	Oral administration validity of insulin, prolonged plasma glucose regulation time
Exenatide ³³	IgG Fc modified exenatide loaded by PEG-PLGA nanoparticles	Db/db mice	Oral administration	Obvious hypoglycemic effect compared with oral administration and SC injection of exenatide solution
Insulin ³⁴	Zn-insulin conjugates loaded by PLGA-PEG nanoparticles	N/A	N/A	Enhanced entrapment capacity with small particle size, sufficient stability for long-term storage
Insulin ³⁵	HP-55-coated capsules loaded with microparticles containing PLGA-lipid-PEG nanoparticles	STZ-induced rats	Oral administration	Oral administration validity of insulin, improved cell uptake, extended efficacy time with stable hypoglycemic effect
Plasmid DNA encoding GLP-1 ³⁶	Linear PEI/plasmid DNA nanoparticles coated by DPPC/1,2-dimyristoyl- <i>rac</i> -glycero-3-methoxy PEG-2000 (DMG-PEG)	Balb/c mice and db/db mice	Oral administration	Obvious blood glucose regulation induced by highly expressed GLP-1 gene transfected by NPs

Exenatide ³⁷	PEG- <i>b</i> -(PELG ₅₀ - <i>g</i> -PLL ₃) nanoparticles	STZ-induced rats	S.c. injection	Prolonged plasma duration time and hypoglycemic effect
Exenatide ³⁸	Zn-exenatide conjugates loaded by PEG-PLGA nanoparticles with low molecular weight protamine as oral absorption promoter	SD rats and db/db mice	Oral administration	Oral administration validity, extended efficacy time, higher plasma maximum concentration, enlarged AUC (3.27 folds), enhanced bioavailability compared with s.c. administration
Repaglinide ³⁹	PEG-PLGA nanoparticles	STZ-induced rats	Oral administration	Extended efficacy time
Insulin ¹⁹	Calcium phosphate-PEG-insulin-casein particles	Female non-obese diabetic mice	Oral administration	Oral administration validity
Insulin ⁴⁰	Zn-insulin complexes loaded by PLA-PEG-PLA thermogel	STZ-induced SD rats	S.c. injection	Extended blood glucose regulation time, stable and prolonged plasma insulin concentration
Liraglutide ⁴¹	PCGA-PEG-PCGA hydrogel	ICR mice and db/db mice	S.c. injection	Extended efficacy time
Lixisenatide ⁴²	PLGA-PEG-PLGA/PCGA-PEG-PCGA mixture hydrogel	ICR mice and SD rats	S.c. injection	Prolonged plasma lifespan, extended blood glucose regulation time, 7.6 folds larger AUC
Exenatide ⁴³	Depot-gel-in-microsphere-in-Matrix-gel system	SD rats	S.c. injection	Significant prolonged release time (46 days) with retained blood glucose regulation activity
Insulin ⁴⁴	4-arm-PEG acrylic hydrogel	N/A	N/A	Sensitive glucose-induced oxidation-degradation to achieve sustainable insulin release
Insulin ⁴⁵	Semi-IPN chitosan-PEG-pAAm hydrogel	N/A	N/A	Sensitive glucose-responsiveness, improved swelling ratio, drug loading capacity and entrapment efficiency derived from the increased PEG ratio
Insulin ⁴⁶	Arg-PEA/PEG-DA hybrid hydrogel with TD-1 as transdermal promoter	STZ-induced ICR mice	Transdermal administration	Good biocompatibility, moderate and prolonged blood glucose regulation capacity

79


80 As table 1 displayed, plenty of cases confirm the advantages of PEG as the ingredient of delivery
81 systems. Among these fascinating systems, micelles, vesicles, nanoparticles (NPs), hydrogels and
82 microneedles captured much attention due to their intrinsic properties. For example, micelles and vesicles

83 are able to encapsulate drugs, including but not limited to small-molecule drugs, peptides, proteins, DNA,
84 with high efficiency to achieve efficient administration⁴⁷. Microneedles array is considered as an effective
85 transdermal administration of insulin since its painless, low cost and convenient for self-administration⁴⁸.
86 Pharmacokinetically, transdermal administration like microneedles matrix is able to bypass the “first-pass”
87 elimination and the reduced maximum blood drug concentration also could minimize the risk of side
88 effects⁴⁹.

89 In recent decades, long-acting formulations with stable and controllable drug release profile are
90 gaining much attention. These “intelligent” formulations generally require an adjustable release process to
91 get with the physiological or pathological changes (like blood glucose concentration fluctuation,
92 temperature variation or oxidative conversion of circumstance) to achieve the optimal dosage distribution
93 in the whole release process. For instance, a severe side effect of conventional insulin injections is the
94 excessive hypoglycemia induced by the burst release of insulin in the blood, the efficacy time is also
95 restricted. By contrast, the release profile of intelligent DDSs is more moderate and persistent. Thus, the
96 responsiveness to physiological or pathological changes, in the other words, the stimuli-responsive
97 capacity is one of the crucial features for sustain release formulations.

98 Specifically, glucose-responsive capacity, which is able to inhibit the burst release of drugs to prevent
99 undesirable hypoglycemia events and prolong the plasma glucose regulation time, is important for
100 intelligent formulations in antidiabetic treatments. The glucose-responsive capacity of PEG-based DDSs
101 can be achieved by introducing glucose-sensitive functions. For example, phenylboronic acid (PBA) is able
102 to endow PEG-based DDSs with glucose-responsive capacity. As **scheme 1** demonstrated, there are two
103 forms of PBA compounds in aqueous milieu⁵⁰: uncharged/relatively hydrophobic form and
104 charged/relatively hydrophilic form. Since charged borate is capable of covalently forming a stable
105 hydrophilic complex with glucose through the esterification between boronic acid and *cis*-diol group. This
106 reaction induces the hydrophilic conversion of PBA-contained components in aqueous milieu (like blood),


107 leading to the degradation of PBA-based micelles and the release of insulin loaded by micelles.



Scheme 1. The reversible formation of PBA-glucose complex

111 The earliest report of the reaction between glucose and PBA was reported by Kuivila, Henry G. *et al.*⁵¹.
112 As time goes by, plenty of studies detailed and optimized the application of PBA in the antidiabetic DDSs.
113 However, there are several challenges such as the discrepancy between apparent pKa for application and
114 physiological pH^{52,53} and the insufficient sensitivity to the fluctuation of blood glucose level⁵⁴ impede its
115 further application. Therefore, a number of attempts have been deployed to form the accurate and
116 adjustable glucose-responsive capacity to achieve controllable and sustainable drug release, providing
117 more convenient formulations with better patient compliance.

118 Another case of stimuli-responsive capacity is glucose oxidase (GOx) which has been widely reported as
119 a key component in the PEG-based DDSs. GOx is an enzyme that converts β -D-glucose and oxygen into
120 gluconic acid and H_2O_2 ⁵³. The intensive oxidation of H_2O_2 can induce many reactions including the
121 dissociation of oxidation-sensitive materials. Thus, a number of DDSs choose H_2O_2 as the initiator of carrier
122 degradation. However, the tissue inflammation induced by H_2O_2 is a challenge of GOx-based
123 glucose-responsive DDSs⁵⁵. In general, the complexes of PEG and stimuli-responsive ingredients, because
124 of their sustainable and controllable drug release capacity, are gradually being developed as a promising
125 antidiabetic DDSs.



129 In this review, we discussed the application of PEG and PEGylated DDSs in the antidiabetic treatments
130 by introducing several novel delivery systems and emphasizing the combination of PEGylated antidiabetic
131 DDSs and stimuli-responsive capacity. In order to further illustrate the extensive applications of PEG in
132 antidiabetic DDSs, several instances are provided below with a detailed description.


133 2 PEGylated micelles in antidiabetic treatments

134 Among all kinds of micelles, the amphiphilic block copolymeric micelle draws much attention as DDSs⁵⁶.
135 Amphiphilic block copolymeric micelles are a series of thermodynamically stable colloidal dispersions
136 consisting of amphiphilic block copolymers, being of diverse strengths such as stabilizing drugs, targeting
137 delivery, enhancing cellular uptake^{57,58}. Three types of amphiphilic copolymeric micelles have been applied
138 in the designing of DDSs: micelle-drug complexes are the composites of copolymeric micelles and drugs,
139 micellar microcontainers trap drug molecules into their internal cavities to deliver them, and
140 polyelectrolyte complexes are formed by the electronic interaction between cargoes and carriers, such as
141 the conjugates of cationic block copolymers and polynucleotides⁵⁹.

142 The amphiphilic block copolymeric micelles can be prepared by the self-assembling of the amphiphilic
143 block copolymer chains which consist of two or more types of natural or synthetic polymers with different
144 water affinity. The hydrophobic polymers consist of the internal side of the copolymeric chain and the
145 hydrophilic polymers, like PEG, are placed on the other side to form external surface of micelles. In fact,
146 PEG is considered as a popular ingredient to form amphiphilic micelles⁵⁶. This unique architecture, widely
147 known as the core-shell structure, allow micelles to deliver drugs with poor aqueous solubility in the water
148 phase by loading them in the hydrophobic core of micelles⁶⁰. In the PEG-contained amphiphilic block
149 copolymeric micelles, the inner space of this spherical colloid encapsulates drugs and the outer PEG chains
150 allow the micelle immune to unwanted results such as enzymolysis and aggregation^{61,62}.

151 Many sorts of chemicals are reported in the development of PEG-contained amphiphilic block


152 copolymeric micelles. For instance, synthetic polypeptides have been applied because they are highly
 153 biocompatible and biodegradable. Li Zhao and coworkers chose poly (L-glutamic acid) (PGA) to prepare
 154 monomethoxy PEG-*b*-poly (L-glutamic acid-*co*-N-3-L-glutamylamidophenylboronic acid) which
 155 designated as mPEG-*b*-P (GA-*co*-GPBA) micelles by modifying mPEG-*b*-PGA with 3-amino phenylboronic
 156 acid (APBA) to deliver insulin²². The whole synthetic route can be divided into two major steps (scheme 2).
 157 Firstly, the copolymers mPEG-*b*-PGA were synthesized by the ring-opening polymerization (ROP) of
 158 γ -Benzyl-L-glutamate-N-carboxyanhydride (BLG-NCA) which followed by the debenzylation. Secondly,
 159 APBA molecules were coupled with the pendent carboxyl groups of GA units to afford copolymers
 160 mPEG-*b*-P (GA-*co*-GPBA). Afterwards, insulin was loaded into the hydrophobic core of the micelle via
 161 dialysis method in deionized water.



162 **Scheme 2.** Synthetic route of copolymers prepared by Li Zhao *et al.*
 163
 164

165 The PBA groups in the polymers can interact with excessive blood glucose to form PBA-glucose
 166 complexes. This hydrophilic variation allows the previously hydrophobic polymers to solve in the water
 167 phase and the insulin loaded in advanced scatter in the local environment. Thus, these amphiphilic
 168 copolymeric micelles synthesized in the work of Li Zhao *et al.* exhibited glucose-responsive and adjustable
 169 drug release ability. As **figure 3** exhibited, When the insulin-loaded micelles were added to phosphate
 170 buffer (PB) without any glucose (0 mg/mL), insulin released very slowly: only 12.6% of the total were
 171 released within 3 h. After the concentration of glucose increased to 3.0 mg/mL, obvious release (37.7%)

172 was observed for the subsequent 3 h. Switching the concentration back to 0 mg/mL, insulin release was
173 inhibited, only 7.2% amount was released in the following 3 h. Then, as the concentration return to 3.0
174 mg/mL again, release behavior was recovered, verified by 16.1% release of insulin within 3 h.




175
176 **Figure 3.** The release profile of glucose-responsive mPEG-*b*-P (GA-*co*-GPBA) micelles

177
178 In addition, no significant difference in circular dichroism (CD) spectra was observed between the
179 released insulin and standard insulin sample, demonstrating that the preloaded insulin maintained its
180 conformation after release. *In vitro* cytotoxicity investigation indicated the good biocompatibility of this
181 copolymeric system.

182 This micelle system was prepared by Li Zhao *et al.*, all components of the micelle are biodegradable and
183 biocompatible, allowing safely elimination after the release of insulin. Besides, except for functioning as a
184 hydrophilic group, PEG is also able to balance the increased immunogenicity and protect micelles from
185 proteases⁶³ in these copolymeric systems. CD spectra verified the therapeutic validity of insulin loaded
186 inside micelles. All these features could support the promising prospect of these copolymeric micelles as
187 antidiabetic DDS.

188 Although polypeptides are of many advantages, a fatal demerit of these materials is the vulnerability to
189 proteases which may weaken the protective effect of micelles on the loaded drug. Thus, Wu Gang and
190 coworkers developed complex poly amino acids micelles with proteases resistance²⁴. As **figure 4** showed,
191 PEG and poly (N-isopropylacrylamide) (PNIPAM) complex were employed as the composite shell, while
192 poly (aspartic acid-*co*-aspartic acid phenylboronic acid) designated as P(Asp-*co*-AspPBA) and poly

193 (aspartic acid-*co*-aspartic acid glucosamine-*co*-aspartic acid nitrilotriacetic acid) designated as
 194 P(Asp-*co*-AspGA-*co*-AspNTA) functioned as the composite core. Insulin was connected to the divalent zinc
 195 ions which coordinated with NTA groups located on the P(Asp-*co*-AspGA-*co*-AspNTA) copolymeric chains.
 196 The glucose sensitivity of these composite micelles was derived from the PBA/GA complexation. PNIPAM
 197 played a crucial role in the protection of micelles from proteolysis by collapsing to form a hydrophobic
 198 shield. As expected, the resistance to proteases and improved blood glucose regulation capacity was
 199 observed. Under abnormally high blood glucose level, the interaction between glucose and PBA moieties
 200 gradually leads to the swelling and disassembly of complex micelles and the release of insulin.



201
202
203

Figure 4. Schematic of the preparation and release process of complex micelles prepared by Wu Gang *et al.*²⁴

204 Rujiang Ma *et al.* devised a type of glucose-responsive complex micelle consisting of block copolymer
 205 PEG-*b*-poly (acrylic acid-*co*-acrylamidophenylboronic acid) (PEG-*b*-P(AA-*co*-APBA)) and glycopolymer
 206 poly (acrylic acid-*co*-acrylglucosamine) (P(AA-*co*-AGA))²⁵. In this complex micelle system prepared by
 207 Rujiang Ma and coworkers, PEG chains on the outer layer functioned as a hydrophilic shell against
 208 aggregation. Another ingenious strategy is the introduction of glycopolymer: the most suitable pH for
 209 glucose-responsiveness is the apparent pKa of PBA (around pH 9) which is much higher than physiological
 210 pH (around 7.4), so the glucose sensitivity is restricted under physiological condition. Due to the
 211 complexation between PBA and glycopolymer, the apparent pKa of PBA was decreased and the glucose

212 sensitivity was enhanced.

213 Except for the enzyme degradation, undesirable aggregation is another obstacle to insulin delivery and
214 application. For example, insulin amyloid deposition has been found at the sites of frequent subcutaneous
215 insulin injections⁶⁴. This objectionable aggregation generally means the weakened hypoglycemic activity
216 of insulin²³ and the increase of its immunogenicity⁶⁵. Besides, these deposits also cause trouble in the
217 production, storage and transportation of insulin⁶⁶.

218 In recent decades, nanocage is gradually concerned as an alternative to traditional DDSs and
219 PEGylation is regarded as an effective method of nanocage functionalization to obtain various advanced
220 properties⁶⁷. A PEG-phosphatidylethanolamine (PEG-PE) micelle system was developed to achieve the
221 reversion of insulin aggregation, inspired by the GroEL-GroES chaperonin system of *Escherichia coli*²³.
222 These diblock copolymeric micelles functioned as nanocages to concentration-dependently reverse the
223 dithiothreitol (DTT)-induced insulin aggregation.

224 Insulin is a hypoglycemic protein with 51 amino acids, composed of two chains designated as A chain
225 with 21 amino acids and B chain with 30 amino acids. These two chains are connected by two disulfide
226 bonds between A and B chains. DTT can cut off these two disulfide bonds to afford separated unfolded
227 peptide chains and the interaction between the hydrophobic parts of these chains finally produces the
228 aggregations. Specifically, these nanocages were able to trap A and B chains of insulin cleaved by DTT,
229 screening the interaction between their hydrophobic moieties which is the main factor of sedimentary
230 formation. Besides, the separated A and B chains were able to reconnect with each other to afford native
231 insulin with hypoglycemic activity. This process can be verified by the MALDI-TOF mass spectra and
232 hypoglycemic effect in mice. CD spectroscopy suggested that PEG-PE micelles stabilized the secondary
233 structure of native insulin, preventing chains from false folding.

234 Jun Wang and coworkers devised and prepared a type of cholic acid (CA)-PLGA-*b*-(polyethyleneimine
235 (PEI)-PEG) micelles to load insulin on their surface through electrostatic interaction (**figure 5**)²⁶. An

236 attractive point of this work reported by Jun Wang *et al.* is the combination of PLGA, PEI and PEG. PLGA has
237 been considered as an ideal material to build micro/nano structure for drug delivery^{68,69}. However,
238 according to existing reports, the degradation of PLGA could produce an local acidic atmosphere⁷⁰ which
239 may cause negative effects on the loading proteins and peptides but can be ameliorated by introducing
240 PEI into the delivery system⁷¹. However, the high cytotoxicity of PEI with large molecular weight (such as
241 25kDa) derived from its excessive positive charge impedes its application^{72,73}. Thus, PEG was introduced
242 into the system combining with low molecular weight PEI to ensure the safety of polymeric delivery system,
243 and the validity of these strategies have been confirmed^{73,74}. Insulin was able to efficiently loaded on the
244 cationic polymeric micelles via the electrostatic force between the abundant cations on PEI-PEG layer and
245 insulin. Extended blood glucose regulation time was observed in *in vivo* investigation.





Figure 5. Preparation of the microsphere loaded with CA-PLGA-*b*-(PEI-PEG) micelles-insulin conjugates²⁶.

3 PEGylated vesicles in antidiabetic treatments

Vesicles are a series of particles sharing a similar structure which consist of a lipid bilayer membrane and an internal hollow space separated from the outside. The bilayer membrane is composed of the hydrophilic "heads" which are generally forming the surface of the membrane and hydrophobic "tails" which are buried under "heads". Biologically, vesicles including liposomes and exosomes are of great importance in the transportation, communication and other metabolic processes of various cells. The potential of vesicles as drug delivery systems has been widely reported⁷⁵⁻⁷⁷ such as paclitaxel-loaded exosomes modified by PEG and ligand treating non-small-cell lung carcinoma (NSCLC) with prolonged

257 circulation time⁷⁸.

258 Inspired by bio-generated vesicles, synthetic ones are also have been developed to deliver drugs. For
259 instance, inspired by native vesicles, Wanyi Tai *et al.* devised a biomimetic polymersome nanovesicle
260 system with an acid-sensitive capacity²⁸. This copolymeric vesicle employed PEG as the hydrophilic “heads”
261 and ketal-modified polyserine (PEG-P (Ser-Ketal)) as the hydrophobic “tails” to form the bilayer membrane.
262 Insulin, glucose oxidase (GOx) and catalase (CAT) were loaded in the hollow space of the vesicle. Drugs
263 were well encapsulated while glucose molecules, due to their small size, were able to penetrate into the
264 inside of the copolymer membrane. Afterwards, the interaction between glucose and GOx afforded
265 gluconic acid and H₂O₂, leading to the local pH decrease. Meanwhile, H₂O₂ generated from the
266 aforementioned process was converted to oxygen by CAT to avoid damaging other cellular components
267 and the deactivation of GOx⁷⁹⁻⁸². As the result of pH decrease, the ketals located on the polyserine
268 segments of copolymers dissociated through acidic hydrolysis, causing hydrophilic conversion (**figure 6 B**)
269 of entire copolymers in aqueous phase (like blood). Water-soluble copolymers without ketal moieties
270 solved in the solution and the copolymeric membrane gradually fractured. Finally, insulin loaded in
271 advance was released (**figure 6 A**).




272

273

274

Figure 6. Schematic of the degradation of acid-sensitive diblock copolymer nanovesicles.

275 The PEG-contained copolymeric nanovesicles were prepared by Wanyi Tai *et al.* exhibiting the
276 glucose-responsive capacity. A low level of insulin release was observed under 100 mg/dL glucose or
277 glucose-free condition in PBS buffer over 12 h, compared with the rapid release under hyperglycemic
278 condition. More importantly, with alternative conversion between normoglycemia and hyperglycemia
279 every 2 h, insulin release exhibited a pulsatile trend correspondingly (figure 7).



280
281 **Figure 7.** Pulsatile insulin release profile of PEG-P (Ser-Ketal) nanovesicles.
282


283 Difference up to 3-fold in release rate was observed when the glucose concentration altered. However,
284 this trend gradually diminished as this circulation continued. A possible reason could be the gradual
285 dissociation of vesicles and the leakage of enzymes.

286 Except for Wanyi Tai and coworkers, the applications of vesicles in the antidiabetic DDSs are also
287 studied by others. Anna Kim *et al.* reported a distearoylphosphoethanolamine-PEG (DSPE-PEG)-coated
288 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposomes to reduce the uptake of liposome by
289 reticuloendothelial system (RES) in parenteral administration³⁰. After coated by DSPE-PEG, the liposomes
290 were of more uniform size with enhanced aggregation resistance, and the circulation time was also
291 extended by 1 h.

292 In addition to individually applied, vesicles are also able to combine with other delivery systems.
293 Rachna Rastogi *et al.* developed a poly (caprolactone)-PEG-poly (caprolactone), which designated as
294 PCL-PEG-PCL, copolymeric vesicle system to encapsulated insulin-deoxycholate composite micelles²⁷.

295 Compared with free insulin, the encapsulation efficiency of complex micelles was enhanced by around
296 10-50%. Burst insulin release was weakened and the efficacy time was prolonged by 2 h, but the increased
297 hydrophobicity of the delivery system exerted a negative influence on its pharmacological effects which
298 emphasize the critical role of equilibrium between hydrophilicity and lipophilicity.

299 Another case is microneedles-vesicles composite delivery system. Microneedles (MNs) have been
300 introduced to antidiabetic DDSs to achieve painless transdermal administration which is able to promote
301 patient compliance due to their unique properties⁵³. MNs (**figure 8**) have been extensively explored for the
302 transdermal administration of various substances such as small molecule drugs⁸³, proteins⁸⁴ and particles⁸⁵,
303 and diverse type of MNs including hollow, solid, coated, dissolving and hydrogel forming⁴⁹ are also
304 developed by various materials. The application of MNs in antidiabetic DDSs have been systematically
305 reported^{48,49}.



306
307

Figure 8. Images of different shapes of MNs (A-I)⁴⁸ and different type of MNs including solid MNs (J), hollow MNs (K),

dissolving MNs (L), degradable MNs (M), and bioresponsive MNs (N)⁸⁶.

The painless and efficient transdermal delivery capacity of MNs is derived from their unique architecture. As **figure 9** displayed, stratum corneum (SC) with a thickness of 10–15 μm is considered as the main obstacle for transdermal administration. According to reports, only sufficiently lipophilic substances with molecular weight lower than 500 Da⁸⁷, which is too small for most of the vesicles, could diffuse into SC. As the result, common transdermal administration is restricted for vesicles. Fortunately, nerves are located a few hundred microns below SC⁸⁸. Thus, the painless administration can be achieved through bypassing the SC without or slightly touching nerves, inducing little or no pain. Besides, compared with conventional transdermal formulations which are highly restricted by the diffusion limit of SC, MNs are able to efficiently deliver the diver types of drugs without SC impedance. The introduction of MNs allow the vesicles which are too large to penetrate SC by self-diffuse to cross this screen with high efficiency, and glucose-responsive vesicles endow formulations with sustainable and controllable release, achieving optimal dosage distribution. The MNs-vesicles complex delivery systems integrate both the efficient transdermal administration and glucose-responsive capacity.





Figure 9. The transdermal administration of vesicles performed by microneedles array.

Xiuli Hu *et al.* integrated self-assembling amphiphilic block copolymeric vesicles which were composed of PEG, polyserine and phenylboronic ester (PBE) with microneedles array to form a MNs/vesicles complex delivery system to achieve sustainable and controllable release¹⁸. Cross-linked hyaluronic acid (HA) was adopted to form the microneedle structure. **Figure 10 A** shows the architecture of mPEG-*b*-P (Ser-PBE)

330 vesicles-loaded MNs array. **Figure 10 B** exhibits that excessive blood glucose concentration causes the
 331 disassociation of vesicles and the consequent insulin release. **Figure 10 C** displays that the origin of H_2O_2
 332 which was directly responsible for the dissociation of vesicles is the interaction between GOx encapsulated
 333 in the vesicles and the glucose penetrating into the inside of vesicles.



334
 335 **Figure 10. A** exhibits the architecture of MNs loaded with mPEG-b-P(Ser-PBE) vesicles; **B** displays the glucose-induced
 336 insulin release; **C** is the degradation reaction of copolymeric vesicles.

337
 338 In the presence of H_2O_2 , copolymers lost their PBE groups and transformed to hydrophilic molecules,
 339 being able to solve in the aqueous phase. Consequently, gradual degradation of vesicles led to the release
 340 of preloaded insulin. Xiuli Hu *et al.* adopted the strategy mentioned above to endow the vesicles with
 341 glucose-responsive function: GOx was introduced to catalyze the conversion from glucose to gluconic acid

342 and afford H_2O_2 which is responsible for the disassembly of vesicles. These vesicles were encapsulated into
343 microneedles formed by cross-linked HA, since HA is highly biocompatible with appropriate stiffness to
344 penetrate skin. Once the plasma glucose level was abnormally high, surplus glucose penetrated the HA
345 membrane into the inside of vesicles, reacting with GOx to yield H_2O_2 , leading to the dissociation of
346 vesicles and the release of insulin loaded in advance. The *in vivo* influence was carefully evaluated: the
347 biocompatibility of this formulation was acceptable, along with the negligible hypoglycemic risk. Rapid
348 glucose-responsive insulin release was observed under hyperglycemia and once reaching normoglycemia,
349 the release rate was restrained. On the one hand, the glucose-sensitive drug release capacity of this MNs
350 loaded with mPEG-b-P(Ser-PBE) vesicles reduce the risk of undesirable side effects such as hypoglycemia
351 and potential damage induced by H_2O_2 to cells; on the other hand, this MNs allows the optimized dosage
352 distribution for drug release, significantly prolonged blood glucose regulation time and administration
353 interval.

354 In another case of the composite MNs delivery system reported by Jicheng Yu and co-workers²⁹, a type
355 of MNs matrix containing hypoxia and H_2O_2 dual-sensitive vesicles was developed based on a similar
356 strategy. The loaded copolymeric vesicles, designated as PEG-P (Ser-S-NI) vesicles, were composed of PEG
357 and polyserine modified by 2-nitroimidazole through thioether bridge. The H_2O_2 and hypoxia-responsive
358 capacity derived from the thioether and 2-nitroimidazole respectively. The thioether was transformed to
359 sulfone after reacting with H_2O_2 , this oxidation leading to the hydrophilic conversion of polymer^{89,90}.
360 Simultaneously, 2-nitroimidazole converted to hydrophilic 2-aminoimidazole under hypoxia condition
361 which was mediated by the transformation from glucose to gluconic acid^{91,92}. In this composite system, the
362 hypoxia-responsive 2-nitroimidazole parts enhance the glucose sensitivity of delivery systems, and the
363 H_2O_2 -responsive thioether parts consume excessive H_2O_2 generated by GOx, avoiding negative effects
364 including inflammation.

365

4 PEGylated nanoparticles (NPs) in antidiabetic treatments

The benefits of PEGylation to NPs have been systematically summarized⁹³ and verified by many studies^{20,31-34,36,38,39,94-96}. Basically, PEG as ingredients could resolve the instability of insulin in the harsh formulation conditions, while poly (D, L-lactide-co-glycolide acid) (PLGA) is a type of polymer that has already been successfully applied in biomacromolecule delivery⁶⁹. Yusuf Haggag and coworkers employed double emulsion technique to prepare a series of NPs consisting of poly (D, L-lactic-co-glycolic acid) (PLAG)-PEG diblock polymers to optimize the entrapment efficiency of insulin³¹. According to the experimental results, part of PLGA-PEG polymers via homogenized insulin-loading method optimized their entrapment efficiency and release kinetics of insulin. The *in vivo* studies revealed the aggregation resistance, improved stability and the maximum retention of hypoglycemic bioactivity of insulin during the whole release process. Moreover, the PLGA-PEG diblock copolymeric NP system devised by Yusuf Haggag *et al.* exhibited a marked insulin sustainable release manner.

A similar PLGA-PEG NPs system was designed by Sunandini Chopra and coworkers³⁴. The difference was that they added zinc ions to insulin to form the insulin-Zn hexamers via the chelation first, then co-assembled with PLGA-PEG under a carefully adjusted pH nanoprecipitation condition to form NPs. Finally, after a PBS washing process, the insulin-Zn PLGA-PEG NPs were afforded (**figure 11**). NPs prepared via this complexation between zinc ion and insulin exhibit significant improvement (about 10-fold) in insulin loading capacity.




Figure 11. Schematic of the preparation of insulin-Zn complex and the NPs developed by Sunandini Chopra and

In the work of Shelesh JAIN and Swarnlata SARAF, PEG significantly extended the efficacy time of repaglinide loaded by PLGA-based NPs from 1 day to 1 week with equivalent therapeutic effect³⁹. Two types of NPs designated as RPGNP1 and RPGNP2 were prepared in this work, based on PLGA and mPEG-PLGA copolymer respectively. The loading capacity of pure PLGA NPs was 58.7 ± 1.3 and the mPEG-PLGA was less than the former, being 45.8 ± 1.2 . *In vitro* release experiments indicated that both of these two formulations experienced an initial burst release and a following sustained release process. However, different trends were observed in the *in vivo* investigations. The blood glucose level of diabetic rats treated by PLGA NPs decreased within the first 24 h and began to climb afterward, while the hypoglycemic effect of mPEG-PLGA NPs maintained over 7 d (figure 12). A possible reason could be the different affinity to liver macrophages: RPGNP2 were hardly identified by liver macrophages due to their PEG structure and able to retain for a relatively long time, while RPGNP1 could be rapidly identified and neutralized by liver macrophages without the PEG sheltering effect.




Figure 12. Blood glucose level of different *in vivo* experimental groups in the work of Shelesh JAIN and Swarnlata SARAF.

Yanan Shi *et al.* prepared a different type of PLGA-PEG NPs, with Fc modified for the oral delivery of

404 exenatide³³. Exenatide is a GLP-1 analogue with 39 amino acids. GLP-1 is a versatile peptide generated by
405 the proglucagon gene, mainly produced by the intestinal L-cells⁹⁷. GLP-1 have been widely concerned as
406 incretin hormones to treat diabetes^{98,99}. However, a fatal demerit of natural GLP-1 is extremely short
407 lifespan. Due to the high affinity with plasma dipeptidyl peptidase 4 (DPP-4), GLP-1 can be neutralized
408 within 2 min⁹⁷. By contrast, the half-life of exenatide is 2.4 h¹⁰⁰. The Fc-targeted NPs could bind to Fc
409 receptor which is expressed on the epithelial cells in the small intestine that could help the absorption of
410 NPs. The *in vitro* and *in vivo* studies verified the better cell uptake and hypoglycemia maintaining
411 performance. Their group also developed low molecular weight protamine (LMWP)-contained PEG-PLGA
412 NPs for the oral delivery of Zn-exenatide complexes³⁸. In this delivery system, the LMWP could increase
413 the penetrability of the whole delivery system which was confirmed by the cellular uptake experiment
414 compared with the pure copolymeric delivery system, the bioavailability also exhibited great improvement.

415 Similar to the strategy of Jun Wang *et al.*, using the electrostatic interaction to connect drugs and
416 carriers, Fei Tong prepared PEG-*b*-(PELG₅₀-*g*-PLL₃) polymeric NPs to carry exenatide via electrostatic force
417 between the negative exenatide molecules and positive polymers under pH 7.4 (**figure 13 A**)³⁷. As Fei Tong
418 reported, the loading efficiency of these PEG-*b*-(PELG₅₀-*g*-PLL₃) NPs on exenatide was 12.11%. The
419 cumulative release profile indicated that the release of exenatide displayed a very stable and sustainable
420 manor (**figure 13 B**), and the observation of blood glucose level revealed a significantly prolonged
421 hypoglycemic activity (**figure 13 C**). Besides, alleviated diabetic nephropathy was also observed in this
422 study.





Figure 13. A: formation of exenatide-loaded PEG-b-(PELG₅₀-g-PLL₃) NPs; **B:** cumulative release profile of NPs; **C:** blood glucose concentration of groups treated differently³⁷.


In addition to delivery GLP-1 analogues, according to Tianqi Nie *et al.* reported, plasmids DNA encoding GLP-1 were also able to be delivered by NPs³⁶. DNA formulations are of various advantages but the rapid degradation of pure DNA and the poor ability to cross the mucus layer in the gastrointestinal tract are still the main challenges in their applications^{36,101}. PEI has already been reported widely as an efficient transfection compounds¹⁰²⁻¹⁰⁴. As **figure 14** showed, in the work of Tianqi Nie *et al.*, plasmid DNA encoding GLP-1 was complexed with linear PEI to form NPs. Afterwards, DPPC and 1,2-dimyristoyl-*rac*-glycero-3-mPEG-2000 (DMG-PEG) were adopted to coating NPs, forming linear PEI/plasmid DNA NPs with a hydrophilic and electrostatically neutral shell which could benefit the penetration process of mucus layer since its highly hydrophilic with abundant cationic charges via an exquisite method named as flash nanocomplexation (FNC).



437
438 **Figure 14.** Preparation of linear PEI/plasmid DNA NPs coated by DPPC/DMP-PEG via FNC technology and the expected
439 penetration process through the gastrointestinal tract³⁶.

440
441 *In vitro* investigations indicated the obviously reduced cytotoxicity induced by the DPPC/DMG-PEG
442 shell and the high transfection efficiency in A549 and HeLa cell lines. *In vivo* experiments pointed out the
443 high efficiency of transfection in the lung and liver, while the good biocompatibility was verified by
444 ameliorated liver damage observed in the toxicity evaluation. Besides, stable expression of GLP-1 resulted
445 in sufficient blood glucose regulation capacity, confirming the potential of the FNC-prepared linear
446 PEI/plasmid DNA NPs coated by DPPC/DMP-PEG.

447 In order to further improve the physiochemical properties to promote the insulin delivery capacity of
448 PEGylated NPs, pharmaceutical spray drying was adopted in the preparation of NPs (**figure 15**). Various
449 benefits to drug encapsulation of this formulation technology have been reported^{105,106}.



450
451 **Figure 15.** SEM images of several NPs produced by spray drying collected by Cordin Arpagaus *et al.*¹⁰⁶

452

453 Spray freeze drying (SFD) is deriving from the general spray drying have been applied to prepare NPs
454 as insulin carriers¹⁰⁷. In this technology, the notable advantage is it can maximum retain the insulin's
455 bioactivity due to the drying process under low temperature.

456 Fei Yu *et al.* took the advantage of SFD to form a type of hydroxypropyl methylcellulose
457 phthalate-coated hard gelatin capsules (HP55) loaded with mono-dispersed microparticles containing
458 insulin-loaded PLGA-lipid-PEG nanoparticles (designated as micro-particles@INS-PLGA-lipid-PEG NPs) for
459 oral administration of insulin (**figure 16**), exhibiting excellent entrapment efficiency (92.3%), much more
460 cellular uptake efficiency than the naked insulin and prolonged decreasing blood glucose level in diabetic
461 mice with oral administration³⁵. This kind of NPs combine the advantages of both polymeric NPs and
462 liposomes¹⁰⁸. Three different functional domains constitute the NPs: a hydrophobic PLGA core as the
463 insulin carrier, an amphiphilic middle layer composed of soybean phosphatidylcholine (SPC) promotes the
464 delivery efficiency and a PEG shell provides physiological stability. Gradient insulin release and elimination
465 were observed after oral administration of the prepared LPNs compared with the rapid release rate
466 induced by subcutaneous injection.

467

468 Sampath Malathi and coworkers prepared a series of D- α -tocopherol PEG 1000 succinate
469 (TPGS)-emulsified PEG-capped PLGA NPs (ISTPPLG NPs) for insulin delivery via oral administration³². The
470 rat trials suggested that the ISTPPLG NPs could successfully decrease the serum glucose level and last for
471 24 h. Notably, the ISTPPLG NPs showed a regenerative effect of the liver, kidneys and pancreas on diabetic
472 rats compared to normal control rats.

473

474 **5 PEGylated hydrogels in antidiabetic treatments**

475 Hydrogel is a type of water-swollen networks mainly consisting of polymer¹⁰⁹, and PEG is a widely used

ingredient for hydrogels which have been extensively studied to achieve controllable and sustainable antidiabetic drug delivery. Plenty of studies report the DDSs based on hydrogels^{41-46,110-115}. Basically, a wide range of substrates can be loaded in the PEG-based hydrogel systems due to their unique structural characters: the highly customizable block length of PEG and other components of hydrogel allow the adjustment of equilibrium between hydrophobicity and hydrophilicity, enabling the universality of different molecules¹¹⁶. Another advantage of copolymeric hydrogels is the diverse stimuli-responsive capacity. Thermosensitive, pH-responsive hydrogels and many other species have been developed and applied in DDSs¹¹⁷. Besides, varying the ratio of different components and combining two or more distinct copolymers also could improve loading capacity. Some examples of diabetes treatment are listed below.

Thermosensitive hydrogels are the most investigated stimuli-sensitive species¹¹⁸, already been applied in the delivery of biomacromolecules¹¹⁹. Phase diagrams reveal the conversion between liquid and solid (figure 16). The lower critical solution temperature (LCST) is the lowest temperature that the polymer remains soluble in aqueous solvent which is injectable. Once beyond the LCST, polymer will transfer to solid gel state to form local drug storage.





Figure 16. Phase diagrams mark the lower critical solution temperature (LCST) and the upper critical solution temperature (UCST) as the temperature barriers between monophasic and biphasic mixture¹¹⁷.

Up to date, thermosensitive hydrogels have already been adopted to deliver antidiabetic drugs. Yipei Chen *et al.* described a series of injectable thermosensitive hydrogels to achieve sustained release of liraglutide (lira)⁴¹. The hydrogels were composed by poly (ϵ -caprolactone-*co*-glycolic acid)-PEG-poly

497 (ϵ -caprolactone-*co*-glycolic acid) (PCGA-PEG-PCGA), obtained via typical ROP, being of similar molecular
498 weights while the ratio of ϵ -caprolactone-*co*-glycolide was various. As reported, these biocompatible
499 copolymers were able to convert to gel from aqueous solution as the ambient temperature increased,
500 which means that copolymers loaded lira were injectable under room temperature, once these
501 thermosensitive materials enter the body, they could form stable hydrogels *in situ* to build drug storages
502 and release pre-encapsulated lira continuously. This copolymer hydrogel formulation fulfills the demand of
503 both sustain drug delivery and painless administration. Meanwhile, pancreatic function benefits were
504 observed, indicating the considerable clinical value of these thermosensitive hydrogels.

505 The loaded drug, lira, is a palmitoyl-acylated derivative of GLP-1. As **figure 17** exhibited, the replacement
506 of lysine with arginine at position 34 and the linkage of a 16-carbon fatty acid at position 26¹²⁰ impede the
507 degradation induced by DPP-4¹²¹, extending the half-life of lira (11-13 h) compared with the unmodified
508 GLP-1 (no more than 2 min)¹²². Besides, various pharmacological activities including the normalization of
509 serum glucose level, the regulation of cardiovascular situation¹²³ and the promotion of β -cell
510 proliferation¹²⁴ have been reported.



511
512 **Figure 17.** Structure of liraglutide¹²⁵.
513

514 A PLGA-PEG-PLGA triblock copolymeric thermosensitive hydrogel was reported⁴² as the carrier of
515 another versatile GLP-1 receptor agonists lixisenatide (lixi)¹²⁶⁻¹²⁸ since the electronic interaction between
516 lixi and PLGA-PEG-PLGA benefit the stability of lixi. Except for PLGA-PEG-PLGA, PCGA-PEG-PCGA
517 copolymers and the mixture of these two copolymeric systems were also investigated. According to the
518 literature, blending hydrogels are of more stable degradation performance *in vivo* than PLGA-PEG-PLGA or
519 PCGA-PEG-PCGA hydrogel alone. Most of all, as the pharmacokinetic study of mixture suggesting,

520 remarkable pharmaceutical improvements were observed including prolonged half-life time and enlarged
521 AUC (table 2).

522 **Table 2.** Pharmacokinetic investigation unfolded the enhancement of hydrogel formulation⁴².

sample	C _{max} ^a (ng/mL)	^b T _{max} (h)	^c t _{1/2z} (h)	AUC _(0-last) (h ng/mL) ^d	MRT ^e
free Lixi	106.4	1.0	2.2	378.9	2.8
Lixi/Gel	24.5	0.5	30.3	2891.6	94.6

523 a: maximum plasma concentration; b: time required to reach the maximum plasma concentration; c: plasma half elimination
524 time; d: area under the curve; e: mean retention time.

525
526 Divya Sharma and Jagdish Singh prepared a PLGA-PEG-PLGA copolymeric hydrogel system to load
527 chitosan-zinc-insulin complexes⁴⁰. The complex of insulin and zinc and the application of oleic-modified
528 chitosan polymer significantly stabilized insulin and its distribution process among this thermosensitive
529 injectable hydrogel. *In vivo* investigation indicated the more stable blood concentration of insulin and the
530 prolonged blood glucose regulation time compared with free insulin.

531 Mei Zhang and coworkers⁴⁴ reported an oxidation-responsive hydrogel polymerized by
532 4-arm-PEG20k-SH and H₂O₂-breakable diacrylate (figure 18). Fluorescein isothiocyanate (FITC) insulin and
533 GOx were loaded into the hydrogel network.






Figure 18. A is the preparation process of FITC-insulin/GOx-loaded oxidation-responsive hydrogel; B are the

SEM images of the hydrogels prepared by Mei Zhang *et al.*⁴⁴

The acrylic moieties hanging in the end of the main chains provided oxidation-responsive capacity. The degradation process can be classified into two approaches, affording 5 parts including phenylboronic acid, acrylic acid, thioether moiety. Phenylboronic acid was oxidized by H_2O_2 , experiencing the 1,6/1,4-elimination with relatively high speed compared with the rate of thioether oxidation¹²⁹. This discrepancy pointed out that the decomposition of phenylboronic acid played a major role in the degradation of hydrogels.

A number of natural materials are of good biocompatibility with low cost. The integration of synthetic and native substances might be able to overcome the demerits of each other and combine their strengths, affording drug carriers with ideal properties and acceptable prices. One of the typical biodegradable materials being able to combine with synthetic polymers like PEG to form hydrogel is chitosan (CS). CS is a


548 natural polysaccharide composed of a series of linear copolymers of D-glucosamine and
549 N-acetyl-D-glucosamine¹³⁰. Due to properties such as good biocompatibility and encapsulation capacity
550 of negatively charged proteins and peptides, CS has captured much attention in DDSs^{131,132}. However, CS
551 requires further structural modifications to improve its loading capacity before its application¹³³⁻¹³⁵.
552 PEGylation could be considered as an acceptable method to extend blood half-life time¹³⁶ and further
553 enhance the biocompatibility of CS¹³⁷. Bahman Vasheghani Farahani and coworkers fabricated a
554 glucose-responsive semi IPN hydrogel by free radical cross-linking polymerization of CS, acrylamide (AAM)
555 and PEG, using hydrogen peroxide as the initiator and N, N'-methylenebisacrylamide (MBA) as the
556 crosslinker⁴⁵. Figure 19 displays its exact structure.



557
558 **Figure 19.** SEM image of chitosan semi-IPN hydrogel (A) and insulin loaded chitosan semi-IPN hydrogel (B)⁴⁵.

559

560 The glucose-responsive property was generated mainly by GOx while CAT also contributed. Insulin was
561 loaded inside the hydrogel by the swelling-diffusion technique. Interestingly, increased PEG ratio led to the
562 rise of swelling ratio, drug loading capacities and entrapment efficiency. *In vitro* investigation showed that
563 per 0.1 g of hydrogel released 150 units of insulin under 500 mg/dL of glucose concentration, and the
564 insulin release rate can be flexibly adjusted by altering the ratio of PEG (figure 20).



565

566

567

Figure 20. *In vitro* insulin release profiles of semi IPN hydrogels with different PEG ratio prepared by Bahman Vasheghani Farahani *et al.*⁴⁵

569 **6 Conclusion**

570 Diabetes mellitus is a severe chronic metabolic disorder that causes huge economic losses and physical
571 pain of patients. Numerous DDSs for antidiabetic drugs, including micelles, vesicles, nanoparticles,
572 microneedles and hydrogels, have been developed to achieve efficient and convenient administration. PEG
573 is a series of amphiphilic polymers which have been studied elaborately in DDSs. The PEG modified DDSs
574 allow multiple physiochemical, pharmacokinetic or pharmacodynamic promotions of antidiabetic drugs
575 such as insulin, GLP-1 analogues and others.

576 The large number of combinations between PEG and other natural or synthetic molecules such as
577 chitosan and PLGA provide abundant types of carriers with diverse characters to fulfill complex demands
578 of drugs. Generally, in the micelle systems, PEG functions as the hydrophilic tails to accelerate the
579 self-assembly of amphiphilic copolymers to afford micelles. Besides, the hydrophilic shell formed by PEG is
580 able to shelter micelles and loaded molecules from undesirable enzymolysis. In the meantime, the
581 purposive modified hydrophobic heads of copolymers could endow micelles with stimuli-responsive
582 capacity, such as the phenylboronic acidified hydrophobic heads could perceive the slight fluctuation of
583 blood glucose level, to achieve controllable and sustainable drug release. Basically, due to the
584 sophisticated structures, several ingredients could be loaded inside the PEGylated vesicles simultaneously.
585 Therefore, vesicles could respond to multiple physiological stimuli to perform a promoted release profile.
586 The highly improved drug delivery efficiency of PEGylated NPs also has been proven such as extended *in*
587 *vivo* half-life time. In the designing and preparation of hydrogels, PEG is widely adopted as an ideal
588 component to build these porous networks. The various combinations between PEG and other natural or
589 artificial materials provide plenty of strategies to develop DDSs. For instance, the thermosensitive
590 hydrogels obtained via integrating thermosensitive materials and PEG exhibit significantly extended
591 internal lifespan.

592 This review highlights the advantages and the versatility of PEG in the designing and preparation of
593 antidiabetic DDS. Benefits like extended plasma half-life, reduced aggregation, enhanced delivery
594 efficiency, improved biocompatibility and stimuli-responsive capacity have been summarized. Predictably,
595 PEG will be continuously studied as an important chemical to develop DDS in the treatment of diabetes
596 mellitus.

597

598 **Acknowledgement**

599 This work was supported by National Natural Science Foundation of China (81673296) and National Key
600 R&D Program of China (2018YFA0901701).

601

- 1 Sinclair, A., Saeedi, P., Kaundal, A., Karuranga, S., Malanda, B. & Williams, R. Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 162 (2020) 108078, doi:10.1016/j.diabres.2020.108078.
- 2 Saeedi, P., Salpea, P., Karuranga, S., Petersohn, I., Malanda, B., Gregg, E. W., Unwin, N., Wild, S. H. & Williams, R. Mortality attributable to diabetes in 20–79 years old adults, 2019 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 162 (2020) 108086, doi:10.1016/j.diabres.2020.108086.
- 3 L Castano, a. & Eisenbarth, G. S. Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat, 8 (1990) 647–679, doi:10.1146/annurev.iy.08.040190.003243.
- 4 Simos, Y. V., Spyrou, K., Patila, M., Karouta, N., Stamatis, H., Gournis, D., Dounousi, E. & Peschos, D. Trends of nanotechnology in type 2 diabetes mellitus treatment, *Asian Journal of Pharmaceutical Sciences* (2020), doi:10.1016/j.ajps.2020.05.001.
- 5 Chatzakis, C., Goulis, D. G., Mareti, E., Eleftheriades, M., Zavlanos, A., Dinas, K. & Sotiriadis, A. Prevention of gestational diabetes mellitus in overweight or obese pregnant women: A network meta-analysis, *Diabetes Res Clin Pract*, 158 (2019) 107924, doi:10.1016/j.diabres.2019.107924.
- 6 Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., Shaw, J. E., Bright, D., Williams, R. & Committee, I. D. F. D. A. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition, *Diabetes Res Clin Pract*, 157 (2019) 107843, doi:10.1016/j.diabres.2019.107843.
- 7 Zuo, X., Dong, Z., Zhang, P., Zhang, P., Chang, G., Xiang, Q., Zhu, X., Zhou, J., Qiao, C., Yang, Y., Qin, Y. & Lou, P. Effect of cognitive behavioral therapy on sleep disturbances and quality of life among adults with type 2 diabetes mellitus: A randomized controlled trial, *Nutrition, Metabolism and Cardiovascular Diseases* (2020), doi:10.1016/j.numecd.2020.06.024.
- 8 Razaz, J. M., Rahmani, J., Varkaneh, H. K., Thompson, J., Clark, C. & Abdulazeem, H. M. The health effects of medical nutrition therapy by dietitians in patients with diabetes: A systematic review and meta-analysis: Nutrition therapy and diabetes, *Prim Care Diabetes*, 13 (2019) 399–408, doi:10.1016/j.pcd.2019.05.001.
- 9 Reyes-García, R., Moreno-Pérez, Ó., Tejera-Pérez, C., Fernández-García, D., Bellido-Castañeda, V., López de la Torre Casares, M., Rozas-Moreno, P., Fernández-García, J. C., Marco Martínez, A., Escalada-San Martín, J., Gargallo-Fernández, M., Botana-López, M., López-Fernández, J., González-Clemente, J. M., Jódar-Gimeno, E. & Mezquita-Raya, P. A comprehensive approach to type 2 diabetes mellitus - A recommendation document, *Endocrinología, Diabetes y Nutrición (English ed.)*, 66 (2019) 443–458, doi:10.1016/j.endien.2018.10.013.
- 10 Harris, J. M., Martin, N. E. & Modi, M. Pegylation: a novel process for modifying pharmacokinetics, *Clin Pharmacokinet*, 40 (2001) 539–551, doi:10.2165/00003088-200140070-00005.
- 11 D'Souza A, A. & Shegokar, R. Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications, *Expert Opin Drug Deliv*, 13 (2016) 1257–1275, doi:10.1080/17425247.2016.1182485.
- 12 Li, W., Zhan, P., De Clercq, E., Lou, H. & Liu, X. Current drug research on PEGylation with small molecular agents, *Progress in Polymer Science*, 38 (2013) 421–444, doi:10.1016/j.progpolymsci.2012.07.006.
- 13 Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G. & Misra, A. PEG - a versatile conjugating ligand for drugs and drug delivery systems, *J Control Release*, 192 (2014) 67–81, doi:10.1016/j.jconrel.2014.06.046.
- 14 Wang, J. Z., You, M. L., Ding, Z. Q. & Ye, W. B. A review of emerging bone tissue engineering via PEG

648 conjugated biodegradable amphiphilic copolymers, *Mater Sci Eng C Mater Biol Appl*, 97 (2019) 1021–1035,
649 doi:10.1016/j.msec.2019.01.057.

650 15 Mishra, P., Nayak, B. & Dey, R. K. PEGylation in anti-cancer therapy: An overview, *Asian Journal of*
651 *Pharmaceutical Sciences*, 11 (2016) 337–348, doi:10.1016/j.ajps.2015.08.011.

652 16 Jacob, J., Haponiuk, J. T., Thomas, S. & Gopi, S. Biopolymer based nanomaterials in drug delivery systems:
653 A review, *Materials Today Chemistry*, 9 (2018) 43–55, doi:10.1016/j.mtchem.2018.05.002.

654 17 Fuks, G., Mayap Talom, R. & Gauffre, F. Biohybrid block copolymers: towards functional micelles and
655 vesicles, *Chem Soc Rev*, 40 (2011) 2475–2493, doi:10.1039/c0cs00085j.

656 18 Hu, X., Yu, J., Qian, C., Lu, Y., Kahkoska, A. R., Xie, Z., Jing, X., Buse, J. B. & Gu, Z. H2O2-Responsive
657 Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery, *ACS Nano*, 11
658 (2017) 613–620, doi:10.1021/acsnano.6b06892.

659 19 Morcol, T., Nagappan, P., Nerenbaum, L., Mitchell, A. & Bell, S. J. Calcium
660 phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin, *Int J Pharm*, 277
661 (2004) 91–97, doi:10.1016/j.ijpharm.2003.07.015.

662 20 Wang, W., Liao, L., Zhang, X., Lei, F., Zhang, Y., Liu, G. & Xie, W. An Intelligent Nanoscale Insulin
663 Delivery System, *Molecules (Basel, Switzerland)*, 23 (2018), doi:10.3390/molecules23112945.

664 21 Yu, J., Zhang, Y., Yan, J., Kahkoska, A. R. & Gu, Z. Advances in bioresponsive closed-loop drug delivery
665 systems, *Int J Pharm*, 544 (2018) 350–357, doi:10.1016/j.ijpharm.2017.11.064.

666 22 Zhao, L., Ding, J., Xiao, C., He, P., Tang, Z., Pang, X., Zhuang, X. & Chen, X. Glucose-sensitive
667 polypeptide micelles for self-regulated insulin release at physiological pH, *Journal of Materials*
668 *Chemistry*, 22 (2012), doi:10.1039/c2jm31040f.

669 23 Fang, X., Yang, T., Wang, L., Yu, J., Wei, X., Zhou, Y., Wang, C. & Liang, W. Nano-cage-mediated refolding
670 of insulin by PEG-PE micelle, *Biomaterials*, 77 (2016) 139–148,
671 doi:10.1016/j.biomaterials.2015.11.007.

672 24 Wu, G., Li, C., Liu, X., Lv, J., Ding, Y., Liu, Y., Liu, Y., Huang, F., Shi, L., An, Y. & Ma, R.
673 Glucose-responsive complex micelles for self-regulated delivery of insulin with effective protection
674 of insulin and enhanced hypoglycemic activity in vivo, *Colloids Surf B Biointerfaces*, 180 (2019) 376–383,
675 doi:10.1016/j.colsurfb.2019.05.003.

676 25 Ma, R., Yang, H., Li, Z., Liu, G., Sun, X., Liu, X., An, Y. & Shi, L. Phenylboronic acid-based complex
677 micelles with enhanced glucose-responsiveness at physiological pH by complexation with glycopolymer,
678 *Biomacromolecules*, 13 (2012) 3409–3417, doi:10.1021/bm3012715.

679 26 Wang, J., Li, S., Chen, T., Xian, W., Zhang, H., Wu, L., Zhu, W. & Zeng, Q. Nanoscale cationic micelles
680 of amphiphilic copolymers based on star-shaped PLGA and PEI cross-linked PEG for protein delivery
681 application, *J Mater Sci Mater Med*, 30 (2019) 93, doi:10.1007/s10856-019-6294-y.

682 27 Rastogi, R., Anand, S. & Koul, V. Evaluation of pharmacological efficacy of 'insulin-surfoplex'
683 encapsulated polymer vesicles, *Int J Pharm*, 373 (2009) 107–115, doi:10.1016/j.ijpharm.2009.01.022.

684 28 Tai, W., Mo, R., Di, J., Subramanian, V., Gu, X., Buse, J. B. & Gu, Z. Bio-inspired synthetic nanovesicles
685 for glucose-responsive release of insulin, *Biomacromolecules*, 15 (2014) 3495–3502,
686 doi:10.1021/bm500364a.

687 29 Yu, J., Qian, C., Zhang, Y., Cui, Z., Zhu, Y., Shen, Q., Ligler, F. S., Buse, J. B. & Gu, Z. Hypoxia
688 and H2O2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery, *Nano Lett*, 17 (2017)
689 733–739, doi:10.1021/acs.nanolett.6b03848.

690 30 Kim, A., Yun, M. O., Oh, Y. K., Ahn, W. S. & Kim, C. K. Pharmacodynamics of insulin in polyethylene
691 glycol-coated liposomes, *Int J Pharm*, 180 (1999) 75–81, doi:10.1016/s0378-5173(98)00408-6.

692 31 Haggag, Y., Abdel-Wahab, Y., Ojo, O., Osman, M., El-Gizawy, S., El-Tanani, M., Faheem, A. & McCarron,
693 P. Preparation and in vivo evaluation of insulin-loaded biodegradable nanoparticles prepared from
694 diblock copolymers of PLGA and PEG, *Int J Pharm*, 499 (2016) 236–246, doi:10.1016/j.ijpharm.2015.12.063.

695 32 Malathi, S., Nandhakumar, P., Pandiyan, V., Webster, T. J. & Balasubramanian, S. Novel PLGA-based
696 nanoparticles for the oral delivery of insulin, *Int J Nanomedicine*, 10 (2015) 2207–2218,

697 doi:10.2147/IJN.S67947.

698 33 Shi, Y., Sun, X., Zhang, L., Sun, K., Li, K., Li, Y. & Zhang, Q. Fc-modified exenatide-loaded
699 nanoparticles for oral delivery to improve hypoglycemic effects in mice, *Sci Rep*, 8 (2018) 726,
700 doi:10.1038/s41598-018-19170-y.

701 34 Chopra, S., Bertrand, N., Lim, J. M., Wang, A., Farokhzad, O. C. & Karnik, R. Design of Insulin-Loaded
702 Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation, *ACS Appl Mater*
703 *Interfaces*, 9 (2017) 11440-11450, doi:10.1021/acsami.6b16854.

704 35 Yu, F., Li, Y., Liu, C. S., Chen, Q., Wang, G. H., Guo, W., Wu, X. E., Li, D. H., Wu, W. D. & Chen,
705 X. D. Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG
706 nanoparticles for oral delivery of insulin, *Int J Pharm*, 484 (2015) 181-191,
707 doi:10.1016/j.ijpharm.2015.02.055.

708 36 Nie, T., He, Z., Zhou, Y., Zhu, J., Chen, K., Liu, L., Leong, K. W., Mao, H. Q. & Chen, Y. Surface
709 Coating Approach to Overcome Mucosal Entrapment of DNA Nanoparticles for Oral Gene Delivery of
710 Glucagon-like Peptide 1, *ACS Appl Mater Interfaces*, 11 (2019) 29593-29603, doi:10.1021/acsami.9b10294.

711 37 Tong, F. Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(l-lysine) block
712 copolymer: potential implications on diabetic nephropathy, *Int J Nanomedicine*, 12 (2017) 4663-4678,
713 doi:10.2147/IJN.S136646.

714 38 Zhang, L., Shi, Y., Song, Y., Sun, X., Zhang, X., Sun, K. & Li, Y. The use of low molecular weight
715 protamine to enhance oral absorption of exenatide, *Int J Pharm*, 547 (2018) 265-273,
716 doi:10.1016/j.ijpharm.2018.05.055.

717 39 Jain, S. & Saraf, S. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational
718 approach for the management of type 2 diabetes mellitus, *J Diabetes*, 1 (2009) 29-35,
719 doi:10.1111/j.1753-0407.2008.00001.x.

720 40 Sharma, D. & Singh, J. Long-term glycemic control and prevention of diabetes complications in vivo
721 using oleic acid-grafted-chitosanzinc-insulin complexes incorporated in thermosensitive copolymer,
722 *J Control Release*, 323 (2020) 161-178, doi:10.1016/j.jconrel.2020.04.012.

723 41 Chen, Y., Luan, J., Shen, W., Lei, K., Yu, L. & Ding, J. Injectable and Thermosensitive Hydrogel
724 Containing Liraglutide as a Long-Acting Antidiabetic System, *ACS Appl Mater Interfaces*, 8 (2016)
725 30703-30713, doi:10.1021/acsami.6b09415.

726 42 Zhuang, Y., Yang, X., Li, Y., Chen, Y., Peng, X., Yu, L. & Ding, J. Sustained Release Strategy Designed
727 for Lixisenatide Delivery to Synchronously Treat Diabetes and Associated Complications, *ACS Appl Mater*
728 *Interfaces*, 11 (2019) 29604-29618, doi:10.1021/acsami.9b10346.

729 43 Wang, P., Zhuo, X., Chu, W. & Tang, X. Exenatide-loaded microsphere/thermosensitive hydrogel
730 long-acting delivery system with high drug bioactivity, *Int J Pharm*, 528 (2017) 62-75,
731 doi:10.1016/j.ijpharm.2017.05.069.

732 44 Zhang, M., Song, C. C., Du, F. S. & Li, Z. C. Supersensitive Oxidation-Responsive Biodegradable PEG
733 Hydrogels for Glucose-Triggered Insulin Delivery, *ACS Appl Mater Interfaces*, 9 (2017) 25905-25914,
734 doi:10.1021/acsami.7b08372.

735 45 Farahani, B. V., Ghasemzaheh, H. & Afraz, S. Intelligent semi-IPN chitosan-PEG-PAAm hydrogel for
736 closed-loop insulin delivery and kinetic modeling, *RSC Advances*, 6 (2016) 26590-26598,
737 doi:10.1039/c5ra28188a.

738 46 Zhang, S., Xin, P., Ou, Q., Hollett, G., Gu, Z. & Wu, J. Poly(ester amide)-based hybrid hydrogels for
739 efficient transdermal insulin delivery, *J Mater Chem B*, 6 (2018) 6723-6730, doi:10.1039/c8tb01466c.

740 47 Tanner, P., Baumann, P., Enea, R., Onaca, O., Palivan, C. & Meier, W. Polymeric vesicles: from drug
741 carriers to nanoreactors and artificial organelles, *Accounts of chemical research*, 44 (2011) 1039-1049,
742 doi:10.1021/ar200036k.

743 48 Jin, X., Zhu, D. D., Chen, B. Z., Ashfaq, M. & Guo, X. D. Insulin delivery systems combined with
744 microneedle technology, *Adv Drug Deliv Rev*, 127 (2018) 119-137, doi:10.1016/j.addr.2018.03.011.

745 49 Jana, B. A. & Wadhvani, A. D. Microneedle - Future prospect for efficient drug delivery in diabetes

746 management, *Indian journal of pharmacology*, 51 (2019) 4–10, doi:10.4103/ijp.IJP_16_18.

747 50 Wu, Q., Wang, L., Yu, H., Wang, J. & Chen, Z. Organization of glucose-responsive systems and their
748 properties, *Chem Rev*, 111 (2011) 7855–7875, doi:10.1021/cr200027j.

749 51 Kuivila, H. G., Keough, A. H. & Soboczenski, E. J. ARENEBORONATES FROM DIOLS AND POLYOLS¹, *The Journal*
750 *of Organic Chemistry*, 19 (1954) 780–783, doi:10.1021/jo01370a013.

751 52 Ma, R. & Shi, L. Phenylboronic acid-based glucose-responsive polymeric nanoparticles: synthesis and
752 applications in drug delivery, *Polym. Chem.*, 5 (2014) 1503–1518, doi:10.1039/c3py01202f.

753 53 Shen, D., Yu, H., Wang, L., Khan, A., Haq, F., Chen, X., Huang, Q. & Teng, L. Recent progress in design
754 and preparation of glucose-responsive insulin delivery systems, *J Control Release*, 321 (2020) 236–258,
755 doi:10.1016/j.jconrel.2020.02.014.

756 54 Yang, H., Sun, X., Liu, G., Ma, R., Li, Z., An, Y. & Shi, L. Glucose-responsive complex micelles for
757 self-regulated release of insulin under physiological conditions, *Soft Matter*, 9 (2013),
758 doi:10.1039/c3sm51538a.

759 55 Wang, J., Ye, Y., Yu, J., Kahkoska, A. R., Zhang, X., Wang, C., Sun, W., Corder, R. D., Chen, Z., Khan,
760 S. A., Buse, J. B. & Gu, Z. Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery, *ACS Nano*,
761 12 (2018) 2466–2473, doi:10.1021/acsnano.7b08152.

762 56 Torchilin, V. P. Micellar nanocarriers: pharmaceutical perspectives, *Pharm Res*, 24 (2007) 1–16,
763 doi:10.1007/s11095-006-9132-0.

764 57 Wang, J., Hu, X. & Xiang, D. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide
765 vaccines, *Drug Deliv*, 25 (2018) 1319–1327, doi:10.1080/10717544.2018.1477857.

766 58 Quijia Quezada, C., Azevedo, C. S., Charneau, S., Santana, J. M., Chorilli, M., Carneiro, M. B. & Bastos,
767 I. M. D. Advances in nanocarriers as drug delivery systems in Chagas disease, *Int J Nanomedicine*, 14
768 (2019) 6407–6424, doi:10.2147/IJN.S206109.

769 59 Edgar, J. Y. C. & Wang, H. Introduction for Design of Nanoparticle Based Drug Delivery Systems, *Current*
770 *pharmaceutical design*, 23 (2017) 2108–2112, doi:10.2174/1381612822666161025154003.

771 60 Adams, M. L., Lavasanifar, A. & Kwon, G. S. Amphiphilic block copolymers for drug delivery, *J Pharm*
772 *Sci*, 92 (2003) 1343–1355, doi:10.1002/jps.10397.

773 61 Khoei, S. & Rahmatolahzadeh, R. Synthesis and characterization of pH-responsive and folated
774 nanoparticles based on self-assembled brush-like PLGA/PEG/AEMA copolymer with targeted cancer therapy
775 properties: A comprehensive kinetic study, *Eur J Med Chem*, 50 (2012) 416–427,
776 doi:10.1016/j.ejmech.2012.02.027.

777 62 Ashok, B., Rubinstein, I., Tsueshita, T. & Onyuksel, H. Effects of peptide molecular mass and PEG chain
778 length on the vasoreactivity of VIP and PACAP(1–38) in pegylated phospholipid micelles, *Peptides*, 25
779 (2004) 1253–1258, doi:10.1016/j.peptides.2004.05.013.

780 63 Schoch, R. L., Emilsson, G., Dahlin, A. B. & Lim, R. Y. H. Protein exclusion is preserved by temperature
781 sensitive PEG brushes, *Polymer*, 132 (2017) 362–367, doi:10.1016/j.polymer.2017.10.063.

782 64 Akbarian, M., Ghasemi, Y., Uversky, V. N. & Yousefi, R. Chemical modifications of insulin: Finding
783 a compromise between stability and pharmaceutical performance, *Int J Pharm*, 547 (2018) 450–468,
784 doi:10.1016/j.ijpharm.2018.06.023.

785 65 Fineberg, S. E., Kawabata, T. T., Finco-Kent, D., Fountaine, R. J., Finch, G. L. & Krasner, A. S.
786 Immunological responses to exogenous insulin, *Endocr Rev*, 28 (2007) 625–652, doi:10.1210/er.2007-0002.

787 66 Siposova, K., Pospiskova, K., Bednarikova, Z., Safarik, I., Safarikova, M., Kubovcikova, M., Kopcansky,
788 P. & Gazova, Z. The molecular mass of dextran used to modify magnetite nanoparticles affects insulin
789 amyloid aggregation, *Journal of Magnetism and Magnetic Materials*, 427 (2017) 48–53,
790 doi:10.1016/j.jmmm.2016.10.083.

791 67 Lee, E. J., Lee, N. K. & Kim, I. S. Bioengineered protein-based nanocage for drug delivery, *Adv Drug*
792 *Deliv Rev*, 106 (2016) 157–171, doi:10.1016/j.addr.2016.03.002.

793 68 Kapoor, D. N., Bhatia, A., Kaur, R., Sharma, R., Kaur, G. & Dhawan, S. PLGA: a unique polymer for drug
794 delivery, *Ther Deliv*, 6 (2015) 41–58, doi:10.4155/tde.14.91.

795 69 Ding, D. & Zhu, Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular
796 therapeutics, *Mater Sci Eng C Mater Biol Appl*, 92 (2018) 1041–1060, doi:10.1016/j.msec.2017.12.036.

797 70 Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A. & Preat, V. PLGA-based nanoparticles:
798 an overview of biomedical applications, *J Control Release*, 161 (2012) 505–522,
799 doi:10.1016/j.jconrel.2012.01.043.

800 71 Kang, H. C., Lee, J. E. & Bae, Y. H. Nanoscaled buffering zone of charged (PLGA)_n-b-bPEI micelles in
801 acidic microclimate for potential protein delivery application, *J Control Release*, 160 (2012) 440–450,
802 doi:10.1016/j.jconrel.2012.02.024.

803 72 Zhang, Y., Lin, L., Liu, L., Liu, F., Maruyama, A., Tian, H. & Chen, X. Ionic-crosslinked
804 polysaccharide/PEI/DNA nanoparticles for stabilized gene delivery, *Carbohydr Polym*, 201 (2018) 246–256,
805 doi:10.1016/j.carbpol.2018.08.063.

806 73 Dong, X., Tian, H., Chen, L., Chen, J. & Chen, X. Biodegradable mPEG-b-P(MCC-g-OEI) copolymers for
807 efficient gene delivery, *J Control Release*, 152 (2011) 135–142, doi:10.1016/j.jconrel.2011.03.025.

808 74 Huang, F. W., Wang, H. Y., Li, C., Wang, H. F., Sun, Y. X., Feng, J., Zhang, X. Z. & Zhuo, R. X. PEGylated
809 PEI-based biodegradable polymers as non-viral gene vectors, *Acta Biomater*, 6 (2010) 4285–4295,
810 doi:10.1016/j.actbio.2010.06.016.

811 75 Vader, P., Mol, E. A., Pasterkamp, G. & Schiffelers, R. M. Extracellular vesicles for drug delivery,
812 *Adv Drug Deliv Rev*, 106 (2016) 148–156, doi:10.1016/j.addr.2016.02.006.

813 76 Ha, D., Yang, N. & Nadithe, V. Exosomes as therapeutic drug carriers and delivery vehicles across
814 biological membranes: current perspectives and future challenges, *Acta pharmaceutica Sinica. B*, 6 (2016)
815 287–296, doi:10.1016/j.apsb.2016.02.001.

816 77 Surman, M., Drożdż, A., Stępień, E. & Przybyło, M. Extracellular Vesicles as Drug Delivery Systems –
817 Methods of Production and Potential Therapeutic Applications, *Current pharmaceutical design*, 25 (2019)
818 132–154, doi:10.2174/1381612825666190306153318.

819 78 Kim, M. S., Haney, M. J., Zhao, Y., Yuan, D., Deygen, I., Klyachko, N. L., Kabanov, A. V. & Batrakova,
820 E. V. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases:
821 in vitro and in vivo evaluations, *Nanomedicine*, 14 (2018) 195–204, doi:10.1016/j.nano.2017.09.011.

822 79 Liu, Y., Du, J., Yan, M., Lau, M. Y., Hu, J., Han, H., Yang, O. O., Liang, S., Wei, W., Wang, H., Li,
823 J., Zhu, X., Shi, L., Chen, W., Ji, C. & Lu, Y. Biomimetic enzyme nanocomplexes and their use as antidotes
824 and preventive measures for alcohol intoxication, *Nat Nanotechnol*, 8 (2013) 187–192,
825 doi:10.1038/nnano.2012.264.

826 80 Traitel, T., Cohen, Y. & Kost, J. Characterization of glucose-sensitive insulin release systems in
827 simulated in vivo conditions, *Biomaterials*, 21 (2000) 1679–1687, doi:10.1016/s0142-9612(00)00050-8.

828 81 Zhang, K. & Wu, X. Y. Modulated insulin permeation across a glucose-sensitive polymeric composite
829 membrane, *J Control Release*, 80 (2002) 169–178, doi:10.1016/s0168-3659(02)00024-x.

830 82 Zhao, L., Xiao, C., Wang, L., Gai, G. & Ding, J. Glucose-sensitive polymer nanoparticles for
831 self-regulated drug delivery, *Chem Commun (Camb)*, 52 (2016) 7633–7652, doi:10.1039/c6cc02202b.

832 83 Kochhar, J. S., Lim, W. X., Zou, S., Foo, W. Y., Pan, J. & Kang, L. Microneedle integrated transdermal
833 patch for fast onset and sustained delivery of lidocaine, *Mol Pharm*, 10 (2013) 4272–4280,
834 doi:10.1021/mp400359w.

835 84 Ito, Y., Nakahigashi, T., Yoshimoto, N., Ueda, Y., Hamasaki, N. & Takada, K. Transdermal insulin
836 application system with dissolving microneedles, *Diabetes Technol Ther*, 14 (2012) 891–899,
837 doi:10.1089/dia.2012.0096.

838 85 McAllister, D. V., Wang, P. M., Davis, S. P., Park, J. H., Canatella, P. J., Allen, M. G. & Prausnitz,
839 M. R. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles:
840 fabrication methods and transport studies, *Proc Natl Acad Sci U S A*, 100 (2003) 13755–13760,
841 doi:10.1073/pnas.2331316100.

842 86 Zhang, Y., Yu, J., Kahkoska, A. R., Wang, J., Buse, J. B. & Gu, Z. Advances in transdermal insulin
843 delivery, *Adv Drug Deliv Rev*, 139 (2019) 51–70, doi:10.1016/j.addr.2018.12.006.

844 87 Donnelly, R. F., Raj Singh, T. R. & Woolfson, A. D. Microneedle-based drug delivery systems:
845 microfabrication, drug delivery, and safety, *Drug Deliv*, 17 (2010) 187–207,
846 doi:10.3109/10717541003667798.

847 88 Nuxoll, E. E. & Siegel, R. A. BioMEMS devices for drug delivery, *IEEE Eng Med Biol Mag*, 28 (2009) 31–39,
848 doi:10.1109/MEMB.2008.931014.

849 89 Napoli, A., Valentini, M., Tirelli, N., Muller, M. & Hubbell, J. A. Oxidation-responsive polymeric
850 vesicles, *Nat Mater*, 3 (2004) 183–189, doi:10.1038/nmat1081.

851 90 Huo, M., Yuan, J., Tao, L. & Wei, Y. Redox-responsive polymers for drug delivery: from molecular design
852 to applications, *Polym. Chem.*, 5 (2014) 1519–1528, doi:10.1039/c3py01192e.

853 91 Yu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B. & Gu, Z.
854 Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive
855 insulin delivery, *Proc Natl Acad Sci U S A*, 112 (2015) 8260–8265, doi:10.1073/pnas.1505405112.

856 92 Krohn, K. A., Link, J. M. & Mason, R. P. Molecular imaging of hypoxia, *J Nucl Med*, 49 Suppl 2 (2008)
857 129S–148S, doi:10.2967/jnumed.107.045914.

858 93 Suk, J. S., Xu, Q., Kim, N., Hanes, J. & Ensign, L. M. PEGylation as a strategy for improving
859 nanoparticle-based drug and gene delivery, *Adv Drug Deliv Rev*, 99 (2016) 28–51,
860 doi:10.1016/j.addr.2015.09.012.

861 94 Haggag, Y. A., Faheem, A. M., Tambuwala, M. M., Osman, M. A., El-Gizawy, S. A., O'Hagan, B., Irwin,
862 N. & McCarron, P. A. Effect of poly(ethylene glycol) content and formulation parameters on particulate
863 properties and intraperitoneal delivery of insulin from PLGA nanoparticles prepared using the
864 double-emulsion evaporation procedure, *Pharmaceutical development and technology*, 23 (2018) 370–381,
865 doi:10.1080/10837450.2017.1295066.

866 95 Ramachandran, R., Paul, W. & Sharma, C. P. Synthesis and characterization of PEGylated calcium phosphate
867 nanoparticles for oral insulin delivery, *Journal of biomedical materials research. Part B, Applied*
868 *biomaterials*, 88 (2009) 41–48, doi:10.1002/jbm.b.31241.

869 96 Tomar, L., Tyagi, C., Kumar, M., Kumar, P., Singh, H., Choonara, Y. E. & Pillay, V. In vivo evaluation
870 of a conjugated poly(lactide-ethylene glycol) nanoparticle depot formulation for prolonged insulin
871 delivery in the diabetic rabbit model, *Int J Nanomedicine*, 8 (2013) 505–520, doi:10.2147/ijn.S38011.

872 97 Alavi, S. E., Cabot, P. J. & Moyle, P. M. Glucagon-Like Peptide-1 Receptor Agonists and Strategies
873 To Improve Their Efficiency, *Mol Pharm*, 16 (2019) 2278–2295, doi:10.1021/acs.molpharmaceut.9b00308.

874 98 Holst, J. J. & Gromada, J. Role of incretin hormones in the regulation of insulin secretion in diabetic
875 and nondiabetic humans, *Am J Physiol Endocrinol Metab*, 287 (2004) E199–206,
876 doi:10.1152/ajpendo.00545.2003.

877 99 Khan, R., Tomas, A. & Rutter, G. A. Effects on pancreatic Beta and other Islet cells of the
878 glucose-dependent insulinotropic polypeptide, *Peptides*, 125 (2020) 170201,
879 doi:10.1016/j.peptides.2019.170201.

880 100 DeYoung, M. B., MacConell, L., Sarin, V., Trautmann, M. & Herbert, P. Encapsulation of exenatide in
881 poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly
882 formulation for type 2 diabetes, *Diabetes Technol Ther*, 13 (2011) 1145–1154,
883 doi:10.1089/dia.2011.0050.

884 101 Cullis, P. R. & Hope, M. J. Lipid Nanoparticle Systems for Enabling Gene Therapies, *Mol Ther*, 25 (2017)
885 1467–1475, doi:10.1016/j.ymthe.2017.03.013.

886 102 Wang, X., Niu, D., Hu, C. & Li, P. Polyethyleneimine-Based Nanocarriers for Gene Delivery, *Current*
887 *pharmaceutical design*, 21 (2015) 6140–6156, doi:10.2174/1381612821666151027152907.

888 103 Pandey, A. P. & Sawant, K. K. Polyethylenimine: A versatile, multifunctional non-viral vector for
889 nucleic acid delivery, *Mater Sci Eng C Mater Biol Appl*, 68 (2016) 904–918,
890 doi:10.1016/j.msec.2016.07.066.

891 104 Lungwitz, U., Breunig, M., Blunk, T. & Gopferich, A. Polyethylenimine-based non-viral gene delivery
892 systems, *Eur J Pharm Biopharm*, 60 (2005) 247–266, doi:10.1016/j.ejpb.2004.11.011.

893 105 Ziaee, A., Albadarin, A. B., Padrela, L., Femmer, T., O'Reilly, E. & Walker, G. Spray drying of
894 pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization
895 approaches, *Eur J Pharm Sci*, 127 (2019) 300–318, doi:10.1016/j.ejps.2018.10.026.

896 106 Arpagaus, C., Collenberg, A., Rutti, D., Assadpour, E. & Jafari, S. M. Nano spray drying for
897 encapsulation of pharmaceuticals, *Int J Pharm*, 546 (2018) 194–214, doi:10.1016/j.ijpharm.2018.05.037.

898 107 Wanning, S., Suverkrup, R. & Lamprecht, A. Pharmaceutical spray freeze drying, *Int J Pharm*, 488 (2015)
899 136–153, doi:10.1016/j.ijpharm.2015.04.053.

900 108 Grigoras, A. G. Polymer–lipid hybrid systems used as carriers for insulin delivery, *Nanomedicine*, 13
901 (2017) 2425–2437, doi:10.1016/j.nano.2017.08.005.

902 109 Dreiss, C. A. Hydrogel design strategies for drug delivery, *Current Opinion in Colloid & Interface*
903 *Science*, 48 (2020) 1–17, doi:10.1016/j.cocis.2020.02.001.

904 110 Li, K., Yu, L., Liu, X., Chen, C., Chen, Q. & Ding, J. A long-acting formulation of a polypeptide drug
905 exenatide in treatment of diabetes using an injectable block copolymer hydrogel, *Biomaterials*, 34 (2013)
906 2834–2842, doi:10.1016/j.biomaterials.2013.01.013.

907 111 Chen, Y., Li, Y., Shen, W., Li, K., Yu, L., Chen, Q. & Ding, J. Controlled release of liraglutide using
908 thermogelling polymers in treatment of diabetes, *Sci Rep*, 6 (2016) 31593, doi:10.1038/srep31593.

909 112 Choi, S., Baudys, M. & Kim, S. W. Control of blood glucose by novel GLP-1 delivery using biodegradable
910 triblock copolymer of PLGA-PEG-PLGA in type 2 diabetic rats, *Pharm Res*, 21 (2004) 827–831,
911 doi:10.1023/b:pham.0000026435.27086.94.

912 113 Yu, L., Li, K., Liu, X., Chen, C., Bao, Y., Ci, T., Chen, Q. & Ding, J. In vitro and in vivo evaluation
913 of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel,
914 *J Pharm Sci*, 102 (2013) 4140–4149, doi:10.1002/jps.23735.

915 114 Huynh, D. P., Im, G. J., Chae, S. Y., Lee, K. C. & Lee, D. S. Controlled release of insulin from
916 pH/temperature-sensitive injectable pentablock copolymer hydrogel, *J Control Release*, 137 (2009) 20–24,
917 doi:10.1016/j.jconrel.2009.02.021.

918 115 Oak, M. & Singh, J. Chitosan-zinc-insulin complex incorporated thermosensitive polymer for controlled
919 delivery of basal insulin in vivo, *J Control Release*, 163 (2012) 145–153,
920 doi:10.1016/j.jconrel.2012.07.035.

921 116 Wang, Q., Zuo, Z., Cheung, C. K. C. & Leung, S. S. Y. Updates on thermosensitive hydrogel for nasal,
922 ocular and cutaneous delivery, *Int J Pharm*, 559 (2019) 86–101, doi:10.1016/j.ijpharm.2019.01.030.

923 117 Qureshi, D., Nayak, S. K., Maji, S., Anis, A., Kim, D. & Pal, K. Environment sensitive hydrogels for
924 drug delivery applications, *European Polymer Journal*, 120 (2019),
925 doi:10.1016/j.eurpolymj.2019.109220.

926 118 Norouzi, M., Nazari, B. & Miller, D. W. Injectable hydrogel-based drug delivery systems for local cancer
927 therapy, *Drug Discov Today*, 21 (2016) 1835–1849, doi:10.1016/j.drudis.2016.07.006.

928 119 Dutta, K., Das, R., Ling, J., Monibas, R. M., Carballo-Jane, E., Kekec, A., Feng, D. D., Lin, S., Mu,
929 J., Saklatvala, R., Thayumanavan, S. & Liang, Y. In Situ Forming Injectable Thermoresponsive Hydrogels
930 for Controlled Delivery of Biomacromolecules, *ACS omega*, 5 (2020) 17531–17542,
931 doi:10.1021/acsomega.0c02009.

932 120 Vilsboll, T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus,
933 *Expert Opin Investig Drugs*, 16 (2007) 231–237, doi:10.1517/13543784.16.2.231.

934 121 Ryan, G. J., Foster, K. T. & Jobe, L. J. Review of the therapeutic uses of liraglutide, *Clin Ther*,
935 33 (2011) 793–811, doi:10.1016/j.clinthera.2011.06.004.

936 122 Muller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A.,
937 Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A.,
938 Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., Stemmer,
939 K., Tang-Christensen, M., Woods, S. C., DiMarchi, R. D. & Tschop, M. H. Glucagon-like peptide 1 (GLP-1),
940 *Mol Metab*, 30 (2019) 72–130, doi:10.1016/j.molmet.2019.09.010.

941 123 Su, K., Yi, B., Yao, B. Q., Xia, T., Yang, Y. F., Zhang, Z. H. & Chen, C. Liraglutide attenuates renal

942 tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and
943 promoting lipolysis, *Pharmacol Res*, 156 (2020) 104778, doi:10.1016/j.phrs.2020.104778.

944 124 Vilsboll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. H., Kolendorf, K., Krarup, T., Schmitz,
945 O., Zdravkovic, M., Le-Thi, T. & Madsbad, S. Liraglutide, a once-daily human GLP-1 analogue, improves
946 pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients
947 with Type 2 diabetes mellitus, *Diabet Med*, 25 (2008) 152-156, doi:10.1111/j.1464-5491.2007.02333.x.

948 125 Russell-Jones, D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human
949 GLP-1 analogue, *Mol Cell Endocrinol*, 297 (2009) 137-140, doi:10.1016/j.mce.2008.11.018.

950 126 Newsome, J. S. Lixisenatide: A New Option for Managing Type 2 Diabetes, *Journal of Pharmacy Technology*,
951 33 (2017) 195-203, doi:10.1177/8755122517711958.

952 127 Varin, E. M., McLean, B. A. & Lovshin, J. A. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients
953 With Type 2 Diabetes: Review of Cardiovascular Outcome Trials, *Can J Diabetes*, 44 (2020) 68-77,
954 doi:10.1016/j.jcjd.2019.08.011.

955 128 Meng, L., Li, X. Y., Shen, L. & Ji, H. F. Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current
956 Evidence and Therapeutic Opportunities, *Trends Mol Med*, 26 (2020) 597-614,
957 doi:10.1016/j.molmed.2020.02.002.

958 129 Song, C.-C., Ji, R., Du, F.-S. & Li, Z.-C. Oxidation-Responsive Poly(amino ester)s Containing
959 Arylboronic Ester and Self-Immolative Motif: Synthesis and Degradation Study, *Macromolecules*, 46 (2013)
960 8416-8425, doi:10.1021/ma401656t.

961 130 Sorlier, P., Denuziere, A., Viton, C. & Domard, A. Relation between the degree of acetylation and the
962 electrostatic properties of chitin and chitosan, *Biomacromolecules*, 2 (2001) 765-772,
963 doi:10.1021/bm015531+.

964 131 Gong, C., Qi, T., Wei, X., Qu, Y., Wu, Q., Luo, F. & Qian, Z. Thermosensitive Polymeric Hydrogels As
965 Drug Delivery Systems, *Current Medicinal Chemistry*, 20 (2013) 79-94.

966 132 Almeida, A., Araujo, M., Novoa-Carballal, R., Andrade, F., Goncalves, H., Reis, R. L., Lucio, M.,
967 Schwartz, S., Jr. & Sarmiento, B. Novel amphiphilic chitosan micelles as carriers for hydrophobic
968 anticancer drugs, *Mater Sci Eng C Mater Biol Appl*, 112 (2020) 110920, doi:10.1016/j.msec.2020.110920.

969 133 Zhang, C., Ding, Y., Yu, L. L. & Ping, Q. Polymeric micelle systems of hydroxycamptothecin based on
970 amphiphilic N-alkyl-N-trimethyl chitosan derivatives, *Colloids Surf B Biointerfaces*, 55 (2007) 192-199,
971 doi:10.1016/j.colsurfb.2006.11.031.

972 134 Zhou, Y. Y., Du, Y. Z., Wang, L., Yuan, H., Zhou, J. P. & Hu, F. Q. Preparation and pharmacodynamics
973 of stearic acid and poly (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles for
974 10-hydroxycamptothecin, *Int J Pharm*, 393 (2010) 143-151, doi:10.1016/j.ijpharm.2010.04.025.

975 135 Zhang, M., Li, X. H., Gong, Y. D., Zhao, N. M. & Zhang, X. F. Properties and biocompatibility of chitosan
976 films modified by blending with PEG, *Biomaterials*, 23 (2002) 2641-2648,
977 doi:10.1016/s0142-9612(01)00403-3.

978 136 Sugimoto, M., Morimoto, M., Sashiwa, H., Saimoto, H. & Shigemasa, Y. Preparation and characterization
979 of water-soluble chitin and chitosan derivatives, *Carbohydrate Polymers*, 36 (1998) 49-59, doi:Doi
980 10.1016/S0144-8617(97)00235-X.

981 137 Prego, C., Torres, D., Fernandez-Megia, E., Novoa-Carballal, R., Quinoa, E. & Alonso, M. J. Chitosan-PEG
982 nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree, *J Control*
983 *Release*, 111 (2006) 299-308, doi:10.1016/j.jconrel.2005.12.015.